Does Zevra Therapeutics, Inc. have an economic moat?

Based on its FY2025 SEC filings, the Moat Index scores Zevra Therapeutics, Inc. (ZVRA) 40.8 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 70, returns on capital 0, balance-sheet safety 55, capital discipline 44.

How has ZVRA's Moat Score changed over time?

The record logs 2 readings since Jul 17, 2026; the latest reads 40.8 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

The Moat Index

Zevra Therapeutics, Inc.

ZVRA · Healthcare · $726.0M mkt cap · FY2025 filings · Shallow moat ·

Doesn't clear the bar

Shallow moat

The four filters

Pricing power70

Median gross margin 91.0% over 4y, variable.

Returns on capital0

Median ROIC -108.3%, above the 9% hurdle in 0% of years.

Balance-sheet safety55

Net cash position — no leverage risk.

Capital discipline44

Owner earnings trend unclear, share count n/a.

Margin of safety

Above valueOn sale

No price data

Owner earnings (normalized): —
Est. intrinsic value / share: —
Recent price: $12.77
Discount to value: No price data

Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).

Fundamentals

There's no normalized fundamentals series for ZVRA yet — it appears once ingest has processed its filings.

Moat Score history

Moat Score over timeLast scored reading of each day, on the 0–100 scale40.8 / 100

Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.

Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars

None yet — ZVRA has read Shallow moat for every logged capture since Jul 17, 2026.

Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.

Healthcare context

#229 of 440 scored Healthcare companies, ranked by Moat Score.

Nearest peers by Moat Score

#227AURX Nuo Therapeutics, Inc.40.8 out of 100, Shallow moatShallow moat
#228LEXX LEXARIA BIOSCIENCE CORP.40.8 out of 100, Shallow moatShallow moat
#230ECOR electroCore, Inc.40.8 out of 100, Shallow moatShallow moat
#231VYNE VYNE THERAPEUTICS INC.40.8 out of 100, Shallow moatShallow moat

Compare ZVRA with its nearest peers →All Healthcare companies on the Index →

Common questions about ZVRA

Does Zevra Therapeutics, Inc. have an economic moat?: Based on its FY2025 SEC filings, the Moat Index scores Zevra Therapeutics, Inc. (ZVRA) 40.8 out of 100 — a Shallow moat. The four filters behind that score (each 0–100): pricing power 70, returns on capital 0, balance-sheet safety 55, capital discipline 44.
How has ZVRA's Moat Score changed over time?: The record logs 2 readings since Jul 17, 2026; the latest reads 40.8 out of 100 (shallow moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.

Embed this score on your site

One iframe, no script. The badge shows ZVRA’s live Moat Score, updates itself as new filings are scored, and links back here. How it works.

<iframe
  src="https://buylikebuffett.com/embed/ZVRA"
  width="340" height="150" style="border:0"
  title="ZVRA Moat Score — The Moat Index"
  loading="lazy"></iframe>

Scored from primary SEC filings via the public methodology. Educational only — not a recommendation to buy or sell ZVRA. See the disclaimer.